Literature DB >> 16491626

Eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.

Anita Hill1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16491626

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  3 in total

1.  Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study.

Authors:  Zohar Yehoshua; Carlos Alexandre de Amorim Garcia Filho; Renata Portella Nunes; Giovanni Gregori; Fernando M Penha; Andrew A Moshfeghi; Kang Zhang; Srinivas Sadda; William Feuer; Philip J Rosenfeld
Journal:  Ophthalmology       Date:  2013-11-26       Impact factor: 12.079

2.  The structure of OMCI, a novel lipocalin inhibitor of the complement system.

Authors:  Pietro Roversi; Olga Lissina; Steven Johnson; Nurfilza Ahmat; Guido C Paesen; Kerstin Ploss; Wilhelm Boland; Miles A Nunn; Susan M Lea
Journal:  J Mol Biol       Date:  2007-03-30       Impact factor: 5.469

3.  The rational design of affinity-attenuated OmCI for the purification of complement C5.

Authors:  Alex Macpherson; Xiaofeng Liu; Neesha Dedi; Jeffery Kennedy; Bruce Carrington; Oliver Durrant; Sam Heywood; Jean van den Elsen; Alastair D G Lawson
Journal:  J Biol Chem       Date:  2018-07-20       Impact factor: 5.157
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.